In vivo engineering chimeric antigen receptor immune cells with emerging nanotechnologies
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: CAR-T cell therapy research · Nanowire Synthesis and Applications · Nanotechnology research and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries10.1016/S0140-6736(21)00001-5 ↗
2. Novel strategies for cancer treatment: highlights from the 55th IACR Annual Conference10.3390/cancers11081125 ↗
3. Long-term outcomes following CAR T cell therapy: what we know so far10.1038/s41571-023-00754-1 ↗
4. Chemically engineering cells for precision medicine10.1039/D2CS00142J ↗
5. Lymph node-biomimetic scaffold boosts CAR-T therapy against solid tumor10.1093/nsr/nwae018 ↗
6. Lyophilized lymph nodes for improved delivery of chimeric antigen receptor T cells10.1038/s41563-024-01825-z ↗
7. Manufacture of CAR-T cells in the body10.1038/nbt.3898 ↗
8. Cancer-fighting CAR T cells could be made inside body with viral injection10.1038/d41586-023-03969-5 ↗
9. In vivo mRNA CAR T cell engineering via targeted ionizable lipid nanoparticles with extrahepatic tropism10.1002/smll.202304378 ↗
10. CD3-specific antibody-induced active tolerance: from bench to bedside10.1038/nri1000 ↗
11. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape10.1038/s41577-021-00592-1 ↗
12. Ionizable lipid nanoparticle-mediated mRNA delivery for Human CAR T cell engineering10.1021/acs.nanolett.9b04246 ↗
13. Orthogonal design of experiments for optimization of lipid nanoparticles for mRNA engineering of CAR T cells10.1021/acs.nanolett.1c02503 ↗
14. Development of a novel one-step production system for injectable liposomes under GMP10.1080/10837450.2017.1290106 ↗
15. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing10.1038/s41565-020-0669-6 ↗
16. Engineering precision nanoparticles for drug delivery10.1038/s41573-020-0090-8 ↗
17. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification10.1002/hep.29904 ↗
18. In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo10.1038/s41467-020-19486-2 ↗
19. Polyethylenimine PEI F25-LMW allows the long-term storage of frozen complexes as fully active reagents in siRNA-mediated gene targeting and DNA delivery10.1016/j.ejpb.2008.03.014 ↗
20. Injectable supramolecular hydrogels for in situ programming of Car-T cells toward solid tumor immunotherapy
21. Overcoming biological barriers by virus-like drug particles for drug delivery10.1016/j.addr.2023.115134 ↗
22. Engineering cells for therapy and diagnosis10.1038/s44222-024-00198-x ↗
23. In vivo production of CAR-T cells using virus-mimetic fusogenic nanovesicles10.1016/j.scib.2023.11.055 ↗
24. Engineering targeted viral vectors for gene therapy10.1038/nrg2141 ↗
25. Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells10.1136/jitc-2021-002737 ↗
26. T-cell receptor gene transfer exclusively to human CD8(+) cells enhances tumor cell killing10.1182/blood-2012-02-412973 ↗
27. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy10.1146/annurev-pharmtox-010611-134654 ↗
28. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells10.1182/blood.V90.9.3789 ↗
29. In vivo CAR T-cell generation in non-human primates using lentiviral vectors displaying a multi-domain fusion ligand10.1182/blood.2024024523 ↗
30. Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy10.1038/s41409-019-0602-5 ↗
31. CAR-NK cells: a promising cellular immunotherapy for cancer10.1016/j.ebiom.2020.102975 ↗
32. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors10.1056/NEJMoa1910607 ↗
33. In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection10.1111/j.1365-2567.2007.02573.x ↗
34. The impact of hypoxia on tumor-associated macrophages10.1172/JCI84427 ↗
35. M2-Like tumor-associated macrophage-targeted codelivery of STAT6 inhibitor and IKKβ siRNA induces M2-to-M1 repolarization for cancer immunotherapy with low immune side effects10.1021/acscentsci.9b01235 ↗
36. Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment10.1186/s12943-019-1022-2 ↗
37. Immuno-oncologists eye up macrophage targets10.1038/nrd.2016.111 ↗
38. Human chimeric antigen receptor macrophages for cancer immunotherapy10.1038/s41587-020-0462-y ↗
39. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix10.1038/s41416-019-0578-3 ↗
40. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions10.1186/s13045-020-00983-2 ↗
41. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering10.1136/jitc-2022-006292 ↗
42. Targeted In Vivo generation of CAR T and NK cells utilizing an engineered lentiviral vector platform10.1182/blood-2023-189087 ↗
43. CD19-targeted CAR T cells in refractory systemic lupus erythematosus10.1056/NEJMc2107725 ↗
44. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus10.1038/s41591-022-02017-5 ↗
45. Current approaches of nanomedicines in the market and various stage of clinical translation10.1016/j.apsb.2022.02.025 ↗
46. Current research trends of nanomedicines10.1016/j.apsb.2023.05.018 ↗
47. Doxil®--the first FDA-approved nano-drug: lessons learned10.1016/j.jconrel.2012.03.020 ↗
48. Recent clinical successes in liposomal nanomedicines10.53941/ijddp.0201009 ↗
49. Liposomal formulations in clinical use: an updated review10.3390/pharmaceutics9020012 ↗
50. Nanomedicine in cancer therapy10.1038/s41392-023-01536-y ↗
51. Non-Lamellar lyotropic liquid crystalline lipid nanoparticles for the next generation of nanomedicine10.1021/acsnano.8b07961 ↗
52. Lipid nanoparticles for gene delivery10.1016/B978-0-12-800148-6.00002-X ↗
53. Cytosolic delivery of nucleic acids: the case of ionizable lipid nanoparticles10.1002/btm2.10213 ↗
54. Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant10.1056/NEJMoa2119451 ↗
55. COVID-19 vaccines: the status and perspectives in delivery points of view10.1016/j.addr.2020.12.011 ↗
56. mRNA vaccines for COVID-19 and diverse diseases10.1016/j.jconrel.2022.03.032 ↗
57. COVID-19 inflammation and implications in drug delivery10.1016/j.jconrel.2022.04.027 ↗
58. Targeting FR-expressing cells in ovarian cancer with Fab-functionalized nanoparticles: a full study to provide the proof of principle from in vitro to in vivo10.1039/C4NR04426F ↗
59. 1202 In vivo engineering of CAR T cells using a novel targeted LNP-mRNA technology
60. CD3: structure, function, and role of immunostaining in clinical practice10.1002/path.1711730404 ↗
61. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs10.1038/s41565-019-0591-y ↗
62. Lipid nanoparticles produce chimeric antigen receptor T cells with interleukin-6 knockdown in vivo10.1016/j.jconrel.2022.08.033 ↗
63. In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift10.1016/j.biomaterials.2021.121339 ↗
64. CD3-specific antibody-induced immune tolerance involves transforming growth factor-beta from phagocytes digesting apoptotic T cells10.1038/nm1749 ↗
65. In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers10.1038/nnano.2017.57 ↗
66. CAR T cells produced in vivo to treat cardiac injury10.1126/science.abm0594 ↗
67. CD5 expression in human B-cell populations10.1016/S0167-5699(99)01476-0 ↗
68. The immunomodulatory properties of the CD5 lymphocyte receptor in health and disease10.1016/j.coi.2011.03.003 ↗
69. A Combined PD-1/C5a blockade synergistically protects against lung cancer growth and metastasis10.1158/2159-8290.CD-16-1184 ↗
70. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity10.1073/pnas.0907448106 ↗
71. Rapid manufacturing of non-activated potent CAR T cells10.1038/s41551-021-00842-6 ↗
72. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells
73. Progress on modulating tumor-associated macrophages with biomaterials10.1002/adma.201902007 ↗
74. 1514 In vivo CAR-M: redirecting endogenous myeloid cells with mRNA for cancer immunotherapy
75. In situ MUC1-specific CAR engineering of tumor-supportive macrophages stimulates tumoricidal immunity against pancreatic adenocarcinoma10.1016/j.nantod.2023.101805 ↗
76. Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy10.1016/j.jconrel.2023.07.021 ↗
77. Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses10.1126/scitranslmed.aax6337 ↗
78. Convection-enhanced delivery of nanoencapsulated gene locoregionally yielding ErbB2/Her2-specific CAR-macrophages for brainstem glioma immunotherapy10.1186/s12951-023-01810-9 ↗
79. Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy10.1126/scitranslmed.abn1128 ↗
80. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers10.1038/s41467-019-11911-5 ↗
81. Critical process parameters in manufacturing of liposomal formulations of amphotericin B10.1016/j.ijpharm.2019.04.052 ↗
82. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs10.1038/s41578-022-00529-7 ↗
83. Lipid nanoparticle technology for therapeutic gene regulation in the liver10.1016/j.addr.2020.06.026 ↗
84. Zwitterionic phospholipidation of cationic polymers facilitates systemic mRNA delivery to spleen and lymph nodes10.1021/jacs.1c09822 ↗
85. Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters10.1073/pnas.1805358115 ↗
86. Charge-altering releasable transporters (CARTs) for the delivery and release of mRNA in living animals10.1073/pnas.1614193114 ↗
87. Spleen SORT LNP generated in situ CAR T cells extend survival in a mouse model of lymphoreplete B cell lymphoma10.1002/anie.202310395 ↗
88. One-component cationic lipids for systemic mRNA delivery to splenic T cells
89. Imidazole-based synthetic lipidoids for in vivo mRNA delivery into primary T lymphocytes10.1002/anie.202008082 ↗
90. Nanoparticles that deliver RNA to bone marrow identified by in vivo directed evolution10.1021/jacs.8b08976 ↗
91. Analyzing 2000 in vivo drug delivery data points reveals cholesterol structure impacts nanoparticle delivery10.1021/acsnano.8b03640 ↗
92. Constrained nanoparticles deliver siRNA and sgRNA to T cells in vivo without targeting ligands10.1002/adma.201902251 ↗
93. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery10.1038/s41596-022-00755-x ↗
94. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles10.1073/pnas.2109256118 ↗
95. Nanoparticle-mediated co-delivery of notch-1 antibodies and ABT-737 as a potent treatment strategy for triple-negative breast cancer10.1021/acsnano.9b09263 ↗
96. Poly(beta-amino ester)s as gene delivery vehicles: challenges and opportunities10.1080/17425247.2020.1796628 ↗
97. Effect of molecular weight of amine end-modified poly(β-amino ester)s on gene delivery efficiency and toxicity10.1016/j.biomaterials.2012.01.046 ↗
98. Role of integrated cancer nanomedicine in overcoming drug resistance10.1016/j.addr.2013.07.012 ↗
99. Uptake and transfection with polymeric nanoparticles are dependent on polymer end-group structure, but largely independent of nanoparticle physical and chemical properties10.1021/mp3004176 ↗
100. Non-viral gene delivery nanoparticles based on poly(β-amino esters) for treatment of glioblastoma10.1016/j.biomaterials.2011.04.016 ↗